Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to less than 18 Years of Age, Hospitalized With Acute Heart Failure

Trial Profile

Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to less than 18 Years of Age, Hospitalized With Acute Heart Failure

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RELAX-PEDS-PK
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to discontinued.
    • 28 Feb 2017 Planned End Date changed from 1 Dec 2017 to 13 Apr 2018.
    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top